Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who agreed to participate in this clinical trial and submitted the written informed consent~2. Subjects aged 20 to 75 years~3. Essential hypertension patients who are measured more 90mmHg, less than 110mmHg of sitting diastolic blood pressure(SiDBP) at baseline(Day 0)~4. Subject who considered to understand this clinical trial, be cooperative,and able to be followed-up whole of the clinical trial period~Exclusion Criteria:~1. Severe hypertension patients: more 110mmHg of mean SiDBP and/or more 185mmHg of mean Sitting systolic blood pressure(SiSBP)~2. Patients with orthostatic hypotension who has sign and symptom~3. Patients with secondary hypertension~4. Patients who are measured the difference of mean blood pressure of one arm under SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit~5. Patients who cannot stop administration of hypertension medication through the clinical trial period, and can take any other hypertension medication except investigational drugs~6. Patients with significant investigations-abnormal renal function (Creatinine more 1.5 times than upper limit of normal), abnormal liver function(AST, ALT more 2 times than upper limit of normal), severe fatty liver disease needed medication~7. Patients with clinically significant investigations in laboratory test of screening visit~8. Patients with surgical and medical disease that is able to be affect to absorption, distribution, metabolism and excretion~9. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c\>9, regimen change of oral hypoglycemic agent, using insulin)~10. Patients with severe heart disease, ischemic heart disease within 6 months, peripheral vascular disease, Percutaneous transluminal coronary angiography(PTCA), Coronary artery bypass graft(CABG)~11. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia~12. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease~13. Patients with severe cerebrovascular disease~14. Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous~15. Patients with known severe or malignancy retinopathy~16. Patients with hepatitis B or C or HIV positive reaction~17. Patients with the medical histories of malignant tumor within 5 years,except local basal cell carcinoma of the skin~18. Patients who have a story or evidence of alcohol or drug abuse within 2 years~19. Patients with history of allergic reaction to any angiotensin II antagonist~20. Patients with any chronic inflammation disease needed to chronic inflammation therapy~21. Childbearing and breast-feeding women~22. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods~23. Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial~24. Patients with significant investigations-Hypokalemia(Less than 3.5 mmol/L), Hyperkalemia(exceeded 5.5 mmol/L)~25. Patients with sodium ion or body fluid is deplated and not able to correct~26. Subject who are judged unsuitable to participate in this clinical trial by investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1 capsule/day of placebo will be orally administered for the study period (8 weeks)
- Valsartan 80mg (Type: ACTIVE_COMPARATOR): (As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
- Fimasartan 30mg (Type: EXPERIMENTAL): 30mg/day of Fimasartan will be orally administered for the study period (8 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).